Hadassah

Hadassah Genetic Discovery Article Singled Out for Recognition

Monday, Feb 8 2016

The January 2015 article which describes the Hadassah Medical Center’s discovery and cure of a rare genetic blood disease which appeared in Blood, the journal of the American Society of Hematology, has been chosen by the journal as one of ten outstanding publications for 2015.

The articles are selected based on the quality of the work, interest to the field of hematology, the number of citations, and how often the paper was accessed.

In this Hadassah article entitled “Early-Onset Evans Syndrome, Immunodeficiency and Premature Immunosenescence Associated with Tripeptidyl-Peptidase II Deficiency,” Dr. Paulina Stepensky, Bone Marrow Specialist and Senior Physician in Hemato-Oncology, along with her colleagues at Hadassah and in Germany, describe a potentially fatal protein deficiency which leads to immune system problems and a variable propensity toward viral infection.

As they reveal, it is the deficiency of this TPP2 molecule that leads T and B immune system cells to deteriorate prematurely (immunosenescence) and for the patient’s immune system to attack itself (autoimmunity). As the authors state, “TPP2 deficiency is the first primary immunodeficiency linking premature immunosenescence to severe autoimmunity.”

The medical scenario began when Hadassah’s physicians encountered the case of a 21-month-old Palestinian boy with early-onset Evans syndrome (autoimmune anemia), viral infections, and progressive leukopenia (reduction in white blood cells). An older sibling, a girl, had been followed in another hospital from the age of 18 months when she presented with white blood cell loss and anemia. She was treated with intravenous immunoglobulin and steroids, but became increasingly unresponsive to therapy at the age of 33 months. At 37 months, she passed away.

Through gene sequencing, Dr. Stepensky, along with Prof. Orly Elpeleg, head of Hadassah’s Department of Genetic and Metabolic Diseases, identified the damaged gene that led to the TPP2 deficiency. With the help of German researchers, the physicians were able to characterize the mechanism of the disease and the way TPP2 is involved in the proper functioning of the immune system. As Dr. Stepensky explains, “We actually discovered a new mechanism of the immune system, a previously unknown path that leads to premature aging of the immune system, which both allows us to diagnose this disease and will also help us better understand the whole system.”

The boy underwent a stem cell transplant at Hadassah, with donor cells from a healthy sibling. In October 2014, six months after the transplant, his physicians reported that “the child remains well with no infectious, autoimmune or lymphoproliferative manifestations. He is no longer prescribed any immunosuppressive medication. Thus, at this early time point, the clinical features that led to the decision to transplant have resolved.”

The physicians conclude that “the determination of senescent T and B cells should be part of the diagnostic evaluation of any child with refractory multilineage cytopenias (reduction in blood cells).”

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Wednesday, Nov 30 2016

Hadassah Teams Up with Spinal Cord Institute to Study Outcomes of Traumatic Injuries

The medical interventions and outcomes for Israelis with a spinal cord injury (SCI) will now be captured in the Rick Hansen SCI Registry (RHSCIR), thanks to the November 16th launch of a partnership between the Hadassah Medical Organization and the Rick Hansen Institute (RHI), a Canadian-based not-for-profit organization named after the paralympic athlete who suffered a severe spinal cord injury following a car accident.

READ MORE ›
alt_text

Thursday, Nov 17 2016

A Birthday Party in Hadassah’s PICU: Helping a Four-Year-Old Recover

Yehoshua "Shuki" Pepper was crossing a Jerusalem street with an older sibling when a car ran him over. He was rushed to Hadassah Hospital Ein Kerem's Pediatric Intensive Care Unit in fair condition, but he wasn't speaking and subsequent MRIs of his head injury were worrisome.

READ MORE ›
alt_text

Thursday, Nov 17 2016

Ethiopian Pre-Nursing Students: On the Way to Fulfilling a Dream

“I know that some people are fine with looking at a screen all day, but I know I need the human touch--to work with people. I want to be a nurse, " relates Sarah Talala, one of the 18 students of Ethiopian background who were given the opportunity to take a course which enabled them to advance to pre-academic studies at the Hebrew University and then on to nursing school at the Hadassah-Hebrew University Henrietta Szold School of Nursing.

READ MORE ›
alt_text

Monday, Nov 14 2016

Granalix BioTechnologies Introduces Food Additive to Protect Against Neurodegenerative Disease

Granalix BioTechnologies, whose founder and Chief Executive Officer is Hadassah Medical Organization Experimental Neurologist Prof. Ruth Gabizon, has launched a food supplement containing pomegranate oil that has proven to protect against neurodegenerative diseases in pre-clinical models.

READ MORE ›

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Membership Questions

membership@hadassah.org

(800) 664-5646

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Missions Department

missions@hadassah.org

(800) 237-1517

Show More